Arrowstreet Capital
MRNS

Arrowstreet Capital’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Arrowstreet Capital’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-5,875
Closed -$60K – 2574
2020
Q2 		$60K Buy
+5,875
New +$54K ﹤0.01% 2248

Other funds holding MRNS

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Arrowstreet Capital's MRNS Position: Q3 2020 in Review

Arrowstreet Capital sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q3 2020, closing a stake of 5,875 shares — an estimated $60K sold.

Arrowstreet Capital first reported a position in MRNS in Q2 2020 and held it in 1 quarter. The position peaked at $60K in Q2 2020. 77 funds tracked by Wall St. Rank hold MRNS as of Q3 2020.

  • Arrowstreet Capital reported no remaining Marinus Pharmaceuticals, Inc position as of Q3 2020 after selling out during the quarter.
  • Arrowstreet Capital sold 5,875 Marinus Pharmaceuticals, Inc shares in Q3 2020, an estimated $60K.
  • Arrowstreet Capital first reported a position in Marinus Pharmaceuticals, Inc in Q2 2020 and held it in 1 quarter.
  • Arrowstreet Capital's Marinus Pharmaceuticals, Inc position peaked at $60K in Q2 2020.
  • 77 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q3 2020.

Based on Arrowstreet Capital's 13F filing for Q3 2020, filed 12 Nov 2020.